Comparative methodological studies of L-asparaginase encapsulation into erythrocytes

Background. L-asparaginase is an enzyme, widely used in the therapy of acute lymphoblastic leukemia in children and adults, but its use is limited due to a wide range of side effects and anaphylactic reactions. L-asparaginase loaded into erythrocytes can solve these problems. This enzyme is protected from the immune system and plasma proteases due to erythrocyte membrane, but continues to work inside the cell because its membrane is permeable to L-asparagine. Thus, the half-life of the drug increases and anaphylactic reactions reduce. The encapsulation of L-asparaginase into erythrocytes can be performed by various osmotic methods. Each of them is characterized by the amount of encapsulated enzyme, the cell yield, as well as by the quality indices of the survived erythrocytes. An important parameter of each method is the possibility to provide sterility of this dosage form for the clinical use.

The aim of the study was the comparing of three osmotic methods of L-asparaginase encapsulation into erythrocytes (hypo-osmotic lysis, dialysis and flow dialysis) to select the most promising method for clinical use.

Materials and methods. A suspension of erythrocytes of healthy donors (hematocrit 60–70%) was mixed with L-asparaginase from E. сoli. The procedures of hypotonic reversible lysis, dialysis in dialysis bags, or flow dialysis using pediatric dialyzers were performed. The physiological osmolality was restored in suspensions after the procedure by the addition of a hypertonic solution, and they were incubated for 30 min at 37 °C. Then the cells were washed in isotonic phosphate-buffered saline with pH 7.4. Activity of L-asparaginase, volume, hematocrit, hematological indices and osmotic cell fragility of erythrocytes were measured in the suspensions of erythrocytes before and after the enzyme encapsulation procedure.

Results. An optimal osmolality of the hypotonic buffer for each method was selected and was equal to 90–110 mOsm/kg. The yields of encapsulation were 4.2 ± 2.0, 6.0 ± 2.3 and 16.2 ± 2.2 % for hypotonic lysis, dialysis and flow dialysis, respectively. The hematological indices of the obtained erythrocyte-carriers differed from the corresponding parameters of the initial erythrocytes, but did not differ significantly for different methods.

Conclusion. Comparative investigation of mentioned above parameters allowed choosing the method of flow dialysis as the most promising for clinical use.

1. Verma N., Kumar K., Kaur G. et al. L-asparaginase: a promising chemotherapeutic agent. Crit Rev Biotechnol 2007;27(1):45–62. DOI: 10.1080/07388550601173926. PMID: 17364689.

2. van den Berg Н. Asparaginase revisited. Leuk Lymphoma 2011;52(2):168–78. DOI: 10.3109/10428194.2010.537796. PMID: 21281233.

3. Müller H.J., Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28(2):97–113. DOI: 10.1016/S1040-8428(98)00015-8. PMID: 9768345.

4. Graham M.L. Pegaspargase: a review of clinical studies. Adv Drug Del Rev 2003;55(10):1293–302. DOI: 10.1016/S0169-409X(03)00110-8. PMID: 14499708.

5. Alpar H.O., Lewis D.A. Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. Biochem Pharmacol 1985;34(2):257–61. DOI: 10.1016/0006-2952(85)90133-9. PMID: 3966927.

6. Kwon Y.M., Chung H.S., Moon C. et al. L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J Control Release 2009;139(3):182–9. DOI: 10.1016/j.jconrel.2009.06.027. PMID: 19577600.

7. Updike S.J., Wakamiya R.T. Infusion of red blood cell-loaded asparaginase in monkey. J Lab Clin Med 1983;101(5):679–91. PMID: 6187874.

8. Naqi A., DeLoach J.R., Andrews K. et al. Determination of parameters for enzyme therapy using L-asparaginase entrapped in canine erythrocytes. Biotechnol Appl Biochem 1988;10(4):365–72. DOI: 10.1111/j.1470-8744.1988.tb00026.x. PMID: 3219195.

9. De Loach J., Ihler G. A dialysis procedure for loading erythrocytes with enzymes and lipids. Biochim Biophys Acta 1977;496(1):136–45. DOI: 10.1016/0304-4165(77)90121-0. PMID: 836891.

10. Kravtzoff R., Ropars C., Laguerre M. et al. Erythrocytes as carriers for L-asparaginase. Methodological and mouse in vivo studies. J Pharm Pharmacol 1990;42(7):473–6. DOI: 10.1111/j.2042-7158.1990.tb06598.x. PMID: 1980286.

11. Ataullakhanov F.I., Vitvitskiy V.M., Zhabotinskiy A.M. et al. Permeability of human erythrocytes for asparagine. Biokhimiya = Biochemistry 1985;50(10):1733–7 (In Russ.).

12. Sinauridze E.I., Vitvitsky V.M., Pichu- gin A.V. et al. A new chemotherapeutic agent: L-asparaginase entrapped in red blood cells. In: Magnani M., DeLoach J.R. (eds). The Use of Resealed Erythrocytes as Carriers and Bioreactors. Adv Exp Med Biol 1992;326:203–6. DOI: 10.1007/978-1-4615-3030-5_25.

13. Kravtzoff R., Desbois I., Lamagnere J.P., et al. Improved pharmacodynamics of Lasparaginase-loaded in human red blood cells. Eur J Clin Pharm 1996;49(6):465–70. PMID: 8706771.

14. Millán C.G., Marinero M.L., Castañeda A.Z. et al. Drug, enzyme and peptide delivery using erythrocytes as carriers. J Control Release 2004;95(1):27–49. DOI: 10.1016/j.jconrel.2003.11.018. PMID: 15013230.

15. Sinauridze E.I. Method for erythrocytes producing filled with a drug substance. USSR Author’s Certificate N 1469609. December 1, 1988 (In Russ.).

16. Domenech C., Thomas X., Chabaud S. et al. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol 2011;153(1):58–65. DOI: 10.1111/j.1365-2141.2011.08588.x. PMID: 21332712.

17. Hunault-Berger M., Leguay T., Huguet F. et al. A phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study. Am J Hematol 2015;90(9):811–8. DOI: 10.1002/ajh.24093. PMID: 26094614.

18. Lanvers C., Vieira Pinheiro J.P., Hempel G. et al. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem 2002;309(1):117–26. DOI: 10.1016/S0003-2697(02)00232-4. PMID: 12381370.

19. Shcherbachenko I.M., Lisovskaya I.L., Tikhonov V.P. Oxidation-induced calcium-dependent dehydration of normal human red blood cells. Free Radical Res 2007;41(5): 536–45. DOI: 10.1080/10715760601161452. PMID: 17454136.

20. Martinov M.V., Plotnikov A.G., Vitvitsky V.M. et al. Deficiencies of glycolytic enzymes as a possible cause of hemolytic anemia. Biochim Biophys Acta 2000;1474(1):75–87. DOI: 10.1016/S0304-4165(99)00218-4. PMID: 10699493.